Inter Partes Review: Patent Killer No More?

Inter Partes review (IPR) can efficiently invalidate drug patents and potentially convey strategic advantages to follow-on drug makers. However, recent changes in the IPR system foretell a tectonic shift in the landscape. Here we summarize these major changes and discuss the implications for the bio...

Full description

Saved in:
Bibliographic Details
Published inTrends in biotechnology (Regular ed.) Vol. 37; no. 7; pp. 680 - 683
Main Authors Chen, Feng-Chi, Lee, Pin-Shen
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.07.2019
Elsevier Limited
Subjects
Biologics Price Competition and Innovation Act
Biopharmaceuticals
Efficiency
Evidence
Hatch-Waxman Act
Inter partes review
patent infringement
Petitions
State court decisions
Tectonics
Trials
Tribunals & commissions
Validity
United States > US
patent infringement
Inter partes review
Biologics Price Competition and Innovation Act
Hatch-Waxman Act
Online AccessGet full text

Cover

More Information
Summary:Inter Partes review (IPR) can efficiently invalidate drug patents and potentially convey strategic advantages to follow-on drug makers. However, recent changes in the IPR system foretell a tectonic shift in the landscape. Here we summarize these major changes and discuss the implications for the biopharmaceutical community.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0167-7799
1879-3096
DOI:10.1016/j.tibtech.2019.02.006